14161-11-6

Basic information

• Product Name: 3,4,5-TRICHLOROPYRIDAZINE
• Synonyms: 3,4,5-TRICHLOROPYRIDAZINE;3,4,5-TRICHLOROPYRIDAZINE 98%;Einecs 238-006-2;Nsc 75074;3,4,5-Trichloro-1,2-diazine;Pyridazine,3,4,5-trichloro-
• CAS NO: 14161-11-6
• Molecular Formula: C₄HCl₃N₂
• Molecular Weight: 183.42
• EINECS: 238-006-2
• Mol File: 14161-11-6.mol

Chemical Properties

• Melting Point: 56-58 °C
• Boiling Point: 322.8 °C at 760 mmHg
• Flash Point: 178.7 °C
• Appearance: /
• Density: 1.641 g/cm³
• Vapor Pressure: 0.000514mmHg at 25°C
• Refractive Index: 1.578
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -2.14±0.10(Predicted)
• CAS DataBase Reference: 3,4,5-TRICHLOROPYRIDAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4,5-TRICHLOROPYRIDAZINE(14161-11-6)
• EPA Substance Registry System: 3,4,5-TRICHLOROPYRIDAZINE(14161-11-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-36/38-43
• Safety Statements: 26
• RIDADR: 1759
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 14161-11-6(Hazardous Substances Data)

Usage

Uses

Given the limited information available on 3,4,5-Trichloropyridazine, it is challenging to list specific applications. However, based on its chemical structure and the properties of similar compounds, we can hypothesize potential uses in the following areas:
Used in Chemical Synthesis:
3,4,5-Trichloropyridazine could be used as an intermediate or building block in the synthesis of more complex organic compounds, particularly those with potential pharmaceutical or industrial applications. Its chlorine atoms may facilitate further reactions, such as substitution or coupling, to produce desired products.
Used in Pharmaceutical Research:
3,4,5-TRICHLOROPYRIDAZINE's structure may exhibit bioactivity, making it a candidate for drug discovery and development. It could be used as a starting point for designing new molecules with therapeutic potential, particularly if its properties can be fine-tuned through modifications or derivatives.
Used in Material Science:
3,4,5-Trichloropyridazine may have properties that make it suitable for use in the development of new materials, such as polymers or coatings, with specific characteristics, such as improved stability, reactivity, or selectivity.

InChI:InChI=1/C4HCl3N2/c5-2-1-8-9-4(7)3(2)6/h1H

Upstream product

• 932-22-9 4,5-dichloro-2H-pyridazin-3-one 
• 186581-53-3 diazomethane 
• 6262-42-6 1,2,3,3-tetrachlorocyclopropene 
• 932-22-9 4,5-Dichloro-3-hydroxypyridazine 

Downstream Products

• 932-22-9 4,5-dichloro-2H-pyridazin-3-one 
• 89180-50-7 5-amino-3,4-dichloropyridazine 
• 53180-76-0 (3,5-dichloropyridazin-4-yl)amine 
• 27225-85-0 [3-(3-chloro-benzo[b]pyridazino[4,3-e][1,4]oxazin-5-yl)-propyl]-dimethyl-amine 
• 27225-84-9 3-chloro-5-methyl-5H-benzo[b]pyridazino[4,3-e][1,4]oxazine 
• 2843-10-9 N-methyl-2-(10-methyl-10H-benzo[b]pyridazino[3,4-e][1,4]thiazin-4-ylsulfanyl)-aniline 
• 2843-08-5 2-(10H-benzo[b]pyridazino[3,4-e][1,4]thiazin-4-ylsulfanyl)-aniline 
• 64820-77-5 10-benzyl-1-chloro-10H-benzo[b]pyridazino[4,5-e][1,4]oxazine 
• 27225-87-2 5-benzyl-3-chloro-5H-benzo[b]pyridazino[4,3-e][1,4]oxazine 
• 21131-12-4 3,4-Dichloro-5-(4-morpholinyl)pyridazine 
• 2288-74-6 3,5-dichloro-4-methoxypyridazine 
• 63910-32-7 3,4-dichloro-5-methoxy-pyridazine 
• 20744-39-2 4-aminopyridazine 
• 13645-43-7 4,5-dichloro-6-nitropyridazin-3(2H)-one 

Relevant articles and documents

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.

Substituted heteroaryl compounds and compositions and uses thereof (by machine translation)

The invention discloses substituted heteroaryl compounds and compositions thereof and their use. The compounds of formula (I) compound or type shown in (I) a compound represented by stereo isomers, tautomers, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or its prodrug. The invention also provides a pharmaceutical composition, the compounds and pharmaceutical compositions can be regulated protein kinase, particularly Aurora kinase and JAK kinase activity, for the prevention, treatment, treatment and reduce protein kinase, in particular JAK kinase activity mediated diseases or disorders. (by machine translation)

PROCESS FOR THE PRODUCTION OF PYRIDAZINYL-AMIDES IN A ONE-POT SYNTHESIS

Process for the production of compounds (I). their salts, tautomers, or enantiomers; by reaction of compounds (II) their salts, tautomers, or enantiomers; with compounds (III) their salts, tautomers, or enantiomers. And compounds III in the form of their HCl adducts.

PROCESS FOR PREPARING 4-AMINO-PYRIDAZINES

The present invention relates to a process for preparing a pyridazine amine compound of formula V, and to processes for preparing dichloropyridazine amine compounds of formula IVa, IVb, or mixtures thereof. Furthermore, the present invention relates to the novel dichloropyridazine amine compounds of formula IVa, IVb,ormixtures thereof, wherein the amino group is an ethylamino group.

IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF THE GABAA RECEPTOR ACTIVITY.

The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R and R6 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.

Chemical Compounds

The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.

Access to 4-alkylaminopyridazine derivatives via nitrogen-assisted regioselective pd-catalyzed reactions

3-Substituted, 6-substituted, and unsymmetrical 3,6-disubstituted 4-alkylaminopyridazines were prepared from a sequence of three chemo- and regioselective reactions combining amination and palladium-catalyzed cross-coupling reactions, such as reductive dehalogenation and Suzuki-Miyaura reactions. Extension of the methodology to Sonogashira reaction yielded a novel class of 3-substituted pyrrolopyridazines.

TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS

There is provided compounds of formula (I), wherein R1, R2, X, R3 and R4 have meanings given in the description (and which compounds are optionally substituted as indicated in the description), and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. a PIM family kinase, such as PIM-1, PIM-2 and/or PIM-3) is desired and/or required, and particularly in the treatment of cancer or a proliferative disease. There is also provided combinations comprising the compounds of formula (I).

DIAMINO-PYRIDINE, PYRIMIDINE, AND PYRIDAZINE MODULATORS OF THE HISTAMINE H4 RECEPTOR

Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as H4 receptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

Process for the preparation of a 3(2H)-pyridazinone-4- substituted amino 5-chloro derivative

The invention relates to novel processes for the preparation of 5-chloro-4-{3-[N-[2-(3,4-dimethoxyphenyl)-ethyl]-N-methylamino]-propylamino-3(2H) pyridazinone of formula (I) and the pharmaceutically acceptable acid addition salts thereof. An important feature of the invention is using 3,4,5-trichloropyridazone as starting substance of the synthesis.